| 1/4 | US=47 / Câncer Toyota M, Kashima L, Tokino T. CHFR as a potential anticancer target. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 163-76. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. CHFR; AGENTE ANTICANCERIGENO; CHECKPOINT MITOTICO; CHECKPOINT PROFASE; TUBULINA; UBIQUITINA LIGASE E3; MITOSE |
| 2/4 | US=84 / Biol/Mol Zhang YE, Yamashita M. Basic concepts of TGF-B signaling in normal physiology and cancer pathobiology: transforming growth factor-B in cancer therapy: smurfs in TGF-B signaling and regulation of bone homeostasis and cancer. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 155-67. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. |
| 3/4 | US=84 / Biol/Mol Itoh S, Suzuki H, Itoh F, Miyazono K, Kato M. TGF-B in inflammation and fibrosis: negative regulation of the TGF-B family signal pathway by inhibitory smads and their involvement in cancer and fibrosis. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 649-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3. |
| 4/4 | US=90 / Biol/Mol Carraway KL, Yen L, Ingalla E, Sweeney C. EGFR signaling networks: negative regulation of signaling by the EGFR family. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 169-86. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. RECEPTOR EGF; CANCER DE MAMA; ERBB2; REGULADOR NEGATIVO; UBIQUITINA LIGASE E3; CAMUNDONGOS TRANSGENICOS |